BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25962093)

  • 21. Cystic pancreatic neuroendocrine tumors: outcomes of preoperative endosonography-guided fine needle aspiration, and recurrence during long-term follow-up.
    Ridtitid W; Halawi H; DeWitt JM; Sherman S; LeBlanc J; McHenry L; Coté GA; Al-Haddad MA
    Endoscopy; 2015 Jul; 47(7):617-25. PubMed ID: 25763832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study.
    Regenet N; Carrere N; Boulanger G; de Calan L; Humeau M; Arnault V; Kraimps JL; Mathonnet M; Pessaux P; Donatini G; Venara A; Christou N; Bachelier P; Hamy A; Mirallié E
    Surgery; 2016 Mar; 159(3):901-7. PubMed ID: 26590096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors.
    Gaujoux S; Partelli S; Maire F; D'Onofrio M; Larroque B; Tamburrino D; Sauvanet A; Falconi M; Ruszniewski P
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4784-9. PubMed ID: 24057286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors.
    Zhou B; Fang B; Yan S; Wang W
    Clin Lab; 2017 Jul; 63(7):1251-1259. PubMed ID: 28792692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.
    Hasegawa T; Yamao K; Hijioka S; Bhatia V; Mizuno N; Hara K; Imaoka H; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Kinoshita T; Kohsaki T; Nishimori I; Iwasaki S; Saibara T; Hosoda W; Yatabe Y
    Endoscopy; 2014 Jan; 46(1):32-8. PubMed ID: 24218309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual.
    Deng BY; Yang M; Wen JY; Hou SZ; Chen Y; Tian BL; Liu XB; Zhang Y
    Medicine (Baltimore); 2020 Jan; 99(3):e18736. PubMed ID: 32011453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How reliable is the Ki-67 cytological index in grading pancreatic neuroendocrine tumors? A meta-analysis.
    Li J; Lin JP; Shi LH; Wang WJ; Li AQ; Si JM; Chen SJ
    J Dig Dis; 2016 Feb; 17(2):95-103. PubMed ID: 26713749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan.
    Ito T; Lee L; Hijioka M; Kawabe K; Kato M; Nakamura K; Ueda K; Ohtsuka T; Igarashi H
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):574-7. PubMed ID: 25689058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic Neuroendocrine Tumours: The Role of Endoscopic Ultrasound Biopsy in Diagnosis and Grading Based on the WHO 2017 Classification.
    Di Leo M; Poliani L; Rahal D; Auriemma F; Anderloni A; Ridolfi C; Spaggiari P; Capretti G; Di Tommaso L; Preatoni P; Zerbi A; Carnaghi C; Lania A; Malesci A; Repici A; Carrara S
    Dig Dis; 2019; 37(4):325-333. PubMed ID: 30897588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?
    Challis BG; Casey RT; Grossman A; Newell-Price J; Newey P; Thakker RV
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):708-715. PubMed ID: 31505044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review.
    Mauriello C; Napolitano S; Gambardella C; Candela G; De Vita F; Orditura M; Sciascia V; Tartaglia E; Lanza M; Santini L; Conzo G
    Int J Surg; 2015 Sep; 21 Suppl 1():S10-4. PubMed ID: 26118605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors.
    Qadan M; Ma Y; Visser BC; Kunz PL; Fisher GA; Norton JA; Poultsides GA
    J Am Coll Surg; 2014 Feb; 218(2):188-95. PubMed ID: 24321190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Validity of the American Joint Committee on Cancer Eighth Edition TNM Staging System for Surgically Treated and Well-Differentiated Pancreatic Neuroendocrine Tumors: A Comprehensive Analysis of 254 Consecutive Patients From a Large Chinese Institution.
    Yang M; Zhang Y; Zeng L; Ke NW; Tan CL; Tian BL; Xiang B; Liu XB
    Pancreas; 2019; 48(5):613-621. PubMed ID: 31091206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The diagnostic value of FNA biopsy in grading pancreatic neuroendocrine tumors.
    Laskiewicz L; Jamshed S; Gong Y; Ainechi S; LaFemina J; Wang X
    Cancer Cytopathol; 2018 Mar; 126(3):170-178. PubMed ID: 29266776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series.
    Kondo NI; Ikeda Y; Maehara S; Sugimoto R; Nishiyama K; Sakaguchi Y
    JOP; 2013 Jul; 14(4):415-22. PubMed ID: 23846939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms.
    Teo RYA; Teo TZ; Tai DWM; Tan DM; Ong S; Goh BKP
    Surgery; 2019 Apr; 165(4):672-685. PubMed ID: 30558808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors.
    Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J
    Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution.
    Yang M; Tan CL; Zhang Y; Ke NW; Zeng L; Li A; Zhang H; Xiong JJ; Guo ZH; Tian BL; Liu XB
    Medicine (Baltimore); 2016 Jul; 95(28):e4213. PubMed ID: 27428224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.